相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104)
K. D. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lapatax: a phase I study of neoadjuvant lapatinib combined with docetaxel in Her2/neu overexpressing breast cancer (BC). EORTC protocol 10054.
H Bonnefoi et al.
CANCER RESEARCH (2010)
Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.
V. Guarneri et al.
CANCER RESEARCH (2010)
Surgical Complications and the Use of Neoadjuvant Bevacizumab.
M. Golshan et al.
CANCER RESEARCH (2010)
RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.
R O'Regan et al.
CANCER RESEARCH (2010)
Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer.
DA Yardley et al.
CANCER RESEARCH (2010)
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
M. Campone et al.
BRITISH JOURNAL OF CANCER (2009)
Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction
Patrick G. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
Patricia M. LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intensified neoadjuvant chemotherapy in early-responding breast cancer:: Phase III randomized GeparTrio study
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer:: Phase III randomized GeparTrio trial
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
Aman U. Buzdar et al.
CLINICAL CANCER RESEARCH (2007)
分享论文
